These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 32705125)

  • 1. Comment on: Cytopenias among patients with rheumatic diseases using methotrexate: a meta-analysis of randomized controlled clinical trials: reply.
    Vanni KMM; Solomon DH
    Rheumatology (Oxford); 2020 Oct; 59(10):e76. PubMed ID: 32705125
    [No Abstract]   [Full Text] [Related]  

  • 2. Comment on: Cytopenias among patients with rheumatic diseases using methotrexate: a meta-analysis of randomized controlled clinical trials.
    Murray KE; Turk MA; Veale DJ
    Rheumatology (Oxford); 2020 Oct; 59(10):e74-e75. PubMed ID: 32705141
    [No Abstract]   [Full Text] [Related]  

  • 3. The use of methotrexate in childhood rheumatic diseases.
    Wallace CA
    Arthritis Rheum; 1998 Mar; 41(3):381-91. PubMed ID: 9506564
    [No Abstract]   [Full Text] [Related]  

  • 4. Methotrexate--the anchor drug--an introduction.
    Pincus T; Cronstein B; Braun J
    Clin Exp Rheumatol; 2010; 28(5 Suppl 61):S1-2. PubMed ID: 21044424
    [No Abstract]   [Full Text] [Related]  

  • 5. Methotrexate induced lymphoma?
    Bleyer WA
    J Rheumatol; 1998 Mar; 25(3):404-7. PubMed ID: 9517755
    [No Abstract]   [Full Text] [Related]  

  • 6. Mechanisms of action of methotrexate.
    Chan ES; Cronstein BN
    Bull Hosp Jt Dis (2013); 2013; 71 Suppl 1():S5-8. PubMed ID: 24219035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does low-dose methotrexate deserve more respect from clinicians?
    Luu B; Rodway GW
    JAAPA; 2017 May; 30(5):12-15. PubMed ID: 28441215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Underestimation of the efficacy, effectiveness, tolerability, and safety of weekly low-dose methotrexate in information presented to physicians and patients.
    Pincus T; Furer V; Sokka T
    Clin Exp Rheumatol; 2010; 28(5 Suppl 61):S68-79. PubMed ID: 21044437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Hypertransaminemia and methotrexate: not always a toxic effect?].
    Montilla Morales C; López Longo FJ; Moreno Zazo M; Monteagudo Sáez I; Moreno García AC; Carreño Pérez L
    Rev Clin Esp; 1998 Dec; 198(12):822-4. PubMed ID: 9930004
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Reducing toxicity of methotrexate with folic acid].
    Harten P
    Z Rheumatol; 2005 Jun; 64(5):353-8. PubMed ID: 15965822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Absence of transaminase elevation during concomitant methotrexate and isoniazid therapy.
    Ekochin LH; Manadan AM; Aggarwal R; Sequeira W; Block JA
    J Rheumatol; 2009 Sep; 36(9):2127. PubMed ID: 19738229
    [No Abstract]   [Full Text] [Related]  

  • 12. Recommendations for the use of parenteral methotrexate in rheumatic diseases.
    Tornero Molina J; Calvo Alen J; Ballina J; Belmonte MÁ; Blanco FJ; Caracuel MÁ; Carbonell J; Corominas H; Chamizo E; Hidalgo C; Ivorra JR; Marenco JL; Moreno Muelas JV; Muñoz-Fernández S; Nolla JM; Pérez T; Sanmarti R; Trenor P; Urrego C; Vidal J; Rosas Gomez de Salazar J
    Reumatol Clin (Engl Ed); 2018; 14(3):142-149. PubMed ID: 28082032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The rational use of methotrexate in rheumatoid arthritis and other rheumatic diseases.
    Furst DE
    Br J Rheumatol; 1997 Nov; 36(11):1196-204. PubMed ID: 9402864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methotrexate and long-term treatment of rheumatic disease: comment on the article by Kremer.
    Ranganathan P; McLeod HL
    Arthritis Rheum; 2005 Feb; 52(2):670-1; author reply 672. PubMed ID: 15692997
    [No Abstract]   [Full Text] [Related]  

  • 15. Myeloid neoplasms arising after methotrexate therapy for autoimmune rheumatological diseases do not exhibit poor-risk molecular features.
    Wechalekar MD; Zhao LP; Kutyna MM; Hong LE; Li J; Hung K; Scott HS; Brown A; Hahn CC; Kassahn K; Ladon D; Yeung DT; Thomas D; Patnaik M; Proudman S; Ades L; Shah MV; Kok CH; Hiwase DK
    Blood Cancer J; 2024 Jul; 14(1):116. PubMed ID: 39030163
    [No Abstract]   [Full Text] [Related]  

  • 16. [Do DMARDs contibute to impaired healing after surgery? Should they be discontinued before surgery?].
    Glück T; Müller-Ladner U
    Dtsch Med Wochenschr; 2007 Sep; 132(37):1901-4. PubMed ID: 17823884
    [No Abstract]   [Full Text] [Related]  

  • 17. Tumor necrosis factor alpha inhibitors and methotrexate: implications for deployed personnel.
    Martin JJ
    Aviat Space Environ Med; 2005 Dec; 76(12):1162-6. PubMed ID: 16370267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reply to comment on: Changes in immunosuppressive medication because of COVID-19 by patients with chronic inflammatory rheumatic diseases: anxiety was not a major driver.
    Andreica I; Baraliakos X; Braun J
    Clin Exp Rheumatol; 2023 Mar; 41(3):762. PubMed ID: 36622113
    [No Abstract]   [Full Text] [Related]  

  • 19. Medical treatment of adolescents with rheumatic disease.
    Hollister JR
    Adolesc Med; 1998 Feb; 9(1):163-70, vii. PubMed ID: 10961259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between 5,10-methylenetetrahydrofolate reductase C677T gene polymorphism and methotrexate related toxicity in patients with autoimmune diseases receiving folic acid supplementation.
    Speletas M; Papadopoulos N; Daiou C; Katodritou E; Pavlitou-Tsiontsi A; Galanopoulou V
    Ann Rheum Dis; 2005 Dec; 64(12):1791-2. PubMed ID: 16284346
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.